Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
about
Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Utilizing lymphatic cell markers to visualize human lymphatic abnormalities.The LAM Lung Cell and Its Human Cell Models.Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.Recent advances in the management of lymphangioleiomyomatosis.
P2860
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
@en
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
@nl
type
label
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
@en
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
@nl
prefLabel
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
@en
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
@nl
P2860
P1476
Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
@en
P2093
Francis X McCormack
Vera P Krymskaya
P2860
P356
10.1146/ANNUREV-MED-050715-104245
P577
2017-01-01T00:00:00Z